Literature DB >> 26488622

Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.

Brigitte C Widemann1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26488622      PMCID： PMC6675564          DOI： 10.1002/pbc.25798

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  4 in total

1.  Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.

Authors:  Paul A Meyers
Journal:  Pediatr Blood Cancer       Date:  2015-10-21       Impact factor: 3.167

Review 2.  Understanding and managing methotrexate nephrotoxicity.

Authors:  Brigitte C Widemann; Peter C Adamson
Journal:  Oncologist       Date:  2006-06

3.  High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?

Authors:  Paul A Meyers; Carlos Flombaum
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

4.  Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.

Authors:  Brigitte C Widemann; Frank M Balis; AeRang Kim; Matthew Boron; Nalini Jayaprakash; Aiman Shalabi; Michelle O'Brien; Michelle Eby; Diane E Cole; Robert F Murphy; Elizabeth Fox; Percy Ivy; Peter C Adamson
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.